RxDoctor Payments Data

Reena James

Family · Chicago, ILNPI 1962062208

Payments from drug & device makers

$1,316in general payments, 2019–2025

Across 38 payments — averaging $34.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$539
  • Esperion Therapeutics, Inc.$154
  • Gilead$119
  • Novo Nordisk$84
  • Amneal Pharmaceuticals LLC$80
  • Boston Scientific$49
  • plus $291 from 13 others

What the payments were for

  • Travel & lodging$312%
  • Food & beverage$1,28698%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,316 in reported general payments places this provider in the 75th percentile of 4,941 family providers in Illinois.

See all family providers in Illinois

Medicare billing

Part B allowed, 2024
$4,022
Medicare patients
30
Services billed
49

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala164$702,904
GenvoyaElviteg/Cob/Emtri/Tenof Alafen27$116,162
TriumeqAbacavir/Dolutegravir/Lamivudi28$116,067
PrezcobixDarunavir/Cobicistat30$86,098
DovatoDolutegravir Sodium/Lamivudine26$84,736
OdefseyEmtricitab/Rilpiviri/Tenof Ala13$49,972
TivicayDolutegravir Sodium16$48,166
PifeltroDoravirine13$26,988
Darunavir13$21,190
XareltoRivaroxaban18$11,203
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl21$4,257
Albuterol Sulfate HfaAlbuterol Sulfate47$2,085
Atorvastatin Calcium67$718
SynthroidLevothyroxine Sodium15$631
Buprenorphine Hcl15$626

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya$119$819,066191 claims
Viiv Healthcare CompanyTriumeq, Dovato, Tivicay$539$248,96970 claims
AbbVieSynthroid$28$63115 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$80$56542 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,941 family providers in Illinois.

Other family in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →